Analystreport

Adaptimmune Therapeutics PLC - (NASDAQ: ADAP) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $4.00 price target on th...

Adaptimmune Therapeutics plc - American Depositary Shares  (ADAP) 
Last adaptimmune therapeutics plc - american depositary shares earnings: 5/9 07:30 am Check Earnings Report